IL-15 Superagonist SHR-1501 Enhances Immune Responses in Lung Cancer by Modulating Tumor Microenvironment.

Meanwhile, we observed that in the KP tumor‐bearing mice model, the tumors treated with low‐dose SHR‐1501 (5 μg per mouse) showed a highly significant reduction in tumor size, with an average decrease of 57%; however, in the LLC tumor‐bearing mice model, low‐dose SHR‐1501 treatment did not result in a similarly significant reduction in tumor size, with only a 24% reduction.

also in 132,142 other papers

The proportion of PD‐1+ CD8+ T cells showed a downward trend in the SHR‐1501 treatment group, although this did not reach statistical significance (Figure 2D ).

also in 111,027 other papers